


**FIG. 1A**




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 3A




FIG. 3B




FIG. 3C

PDGFRa inhibition on mAb2 CHO-K1 Production					
Day 12 Parameter	Relative IVCC	%Viability	Relative Titer	Relative Qp	
Control	1.00	96.40	1.00	1.00	
+PDGFRai	0.62	94.13	0.75	1.20	
+PDGFRai +insulin	0.77	93.50	0.81	1.05	

FIG. 3D




FIG. 4A





FIG. 4B








FIG. 4D

PDGFRa levels are stabilized during production in PERK KOs**FIG. 5A**

PERK KO on mAb2 CHO-K1 Production				
Day 14 Parameter	Relative IVCC	%Viability	Relative Titer	Relative Qp
WT	1.00	95.9	1.00	1.00
PERK KO 2	0.55	51.5	0.97	1.78
PERK KO 3	0.83	64.9	1.07	1.29
PERK KO 4	0.88	77.9	1.15	1.30
PERK KO 6	0.85	60.3	1.18	1.40
PERK KO 7	0.80	71.4	0.96	1.20

FIG. 5B




FIG. 5C




FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D



mRNA Levels Rich Prod. Media




FIG. 6E Continued




FIG.7A

Fab1 Day 14 Bioprocessing Outcom
Rich Production Media




FIG. 7B